Epitranscriptomic editing of the RNA N6-methyladenosine modification by dCasRx conjugated methyltransferase and demethylase

• Published in: Nucleic acids research Vol. 49; no. 13; pp. 7361 - 7374
• Main Authors: Xia, Zhen, Tang, Min, Ma, Jiayan, Zhang, Hongyan, Gimple, Ryan C, Prager, Briana C, Tang, Hongzhen, Sun, Chongran, Liu, Fuyi, Lin, Peng, Mei, Yutang, Du, Ruoxin, Rich, Jeremy N, Xie, Qi
• Format: Journal Article
• Language: English
• Published: Oxford University Press 21.07.2021
• Subjects: Gene regulation, Chromatin and Epigenetics
• ISSN: 0305-1048; 1362-4962
• DOI: 10.1093/nar/gkab517

Abstract N6-methyladenosine (m6A) is a common modification on endogenous RNA transcripts in mammalian cells. Technologies to precisely modify the RNA m6A levels at specific transcriptomic loci empower interrogation of biological functions of epitranscriptomic modifications. Here, we developed a bidirectional dCasRx epitranscriptome editing platform composed of a nuclear-localized dCasRx conjugated with either a methyltransferase, METTL3, or a demethylase, ALKBH5, to manipulate methylation events at targeted m6A sites. Leveraging this platform, we specifically and efficiently edited m6A modifications at targeted sites, reflected in gene expression and cell proliferation. We employed the dCasRx epitranscriptomic editor system to elucidate the molecular function of m6A-binding proteins YTHDF paralogs (YTHDF1, YTHDF2 and YTHDF3), revealing that YTHDFs promote m6A-mediated mRNA degradation. Collectively, our dCasRx epitranscriptome perturbation platform permits site-specific m6A editing for delineating of functional roles of individual m6A modifications in the mammalian epitranscriptome.